This study compares the probability of disease progression, progression-free survival, and overall survival between patients undergoing an allogeneic or autologous transplant for multiple myeloma using an identical preparative regimen. Patients received a preparative regimen of TBI, busulfan, and cyclophosphamide followed by an allogeneic or autologous transplant. In the allogeneic group (n = 21), six patients received bone marrow and 15 received G-CSF mobilized PBSC; all autologous patients (n = 35) received PBSC mobilized with cyclophosphamide and G-CSF. Allogeneic donors were HLA-identical (n = 20) or one-antigen mismatched (n = 1) siblings. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus (n = 10), tacrolimus/methotrexate (n = 6), cyclosporine/methotrexate (n = 4), or cyclosporine (n = 1). The groups were evenly matched for gender, pretransplant therapy, disease status at time of transplant, myeloma subtype, and time from diagnosis to transplant. The median age was significantly lower in the allogeneic group (48 vs 55 years, P Ͻ 0.01). In the allogeneic group the probabilities of developing acute GVHD grade II-IV and chronic GVHD were 55% and 82%, respectively. The Kaplan-Meier probability of disease progression was significantly lower in the allogeneic group (11% vs 64%, P Ͻ 0.001) compared to the autologous group. Although progression-free (60% vs 30%, P = 0.19) and overall survival at 2 years (60% vs 42%, P = 0.39) favored the allogeneic group, this did not reach statistical significance. Within the allogeneic transplant group, patients age 50 years or under had a 3-year overall survival significantly higher when compared to older patients (79% vs 29%, P = 0.03). Using identical preparative regimens, allogeneic transplantation reduced disease progression compared to autologous transplantation for myeloma. This suggests that allogeneic transplantation induces a A major advance in the treatment of myeloma has been the observation that high-dose therapy increases the CR rate and induces durable remissions, even in patients with refractory disease. Initial phase II trials of myeloablative therapy with autologous stem cell rescue yielded higher CR rates than were typically seen with conventional therapy, suggesting that high-dose therapy might improve overall survival.
A major advance in the treatment of myeloma has been the observation that high-dose therapy increases the CR rate and induces durable remissions, even in patients with refractory disease. Initial phase II trials of myeloablative therapy with autologous stem cell rescue yielded higher CR rates than were typically seen with conventional therapy, suggesting that high-dose therapy might improve overall survival. 1, 2 This was eventually shown in a randomized, prospective trial conducted by Attal et al. 3 Comparing a preparative regimen of TBI and melphalan with autologous PBSC transplant to conventional dose therapy, Attal et al reported a significantly improved 5-year event-free and overall survival for those receiving high-dose therapy. These findings have been confirmed by other investigators, and autologous transplantation has become a standard therapy for many patients. 4 However autologous transplant is not curative as most patients develop progressive disease within 5 years of receiving high-dose therapy.
Allogeneic transplantation is an attractive treatment option because it uses a tumor-free stem cell source and induces a potential graft-versus-myeloma (GVM) effect. 5 Durable, progression-free survivals have been reported following allogeneic transplantation, but treatment-related toxicities are substantial and often negate a survival advantage over autologous transplantation. 4, 6 Newer, less intense preparative regimens have been devised to reduce the acute toxicities associated with allogeneic transplantation, but trials are ongoing and inconclusive at the present time. 7, 8 It is uncertain if the reduction in disease progression often observed after full intensity allogeneic transplant is a function of the preparative regimen, a GVM effect, or both of these factors. Although a few studies have directly compared autologous and allogeneic transplantation for myeloma, the heterogeneity in preparative regimens makes it difficult to assess the impact of a specific preparative regimen or graft source on outcome. 6, 9, 10 In 1994, the University of Michigan began a trial using allogeneic transplantation for patients with stage II or III multiple myeloma. As many of our patients had received prior melphalan therapy, a preparative regimen of modified TBI, busulfan, and cyclophosphamide was chosen based on data available at that time suggesting that this regimen was sufficiently immunosuppressive to allow allogeneic engraftment and was associated with a low relapse-rate in chemotherapy-refractory patients. 11, 12 In 1997, a trial using the same preparative regimen for patients with multiple myeloma undergoing autologous PBSC transplantation was started. In this report, we compare the results from these two studies to assess the impact of the stem cell source on outcome.
Patients and methods
From March 1994 to January 1999, 56 patients with myeloma were enrolled in either the autologous or allogeneic transplant study. Analyses of data were updated to November 1999. All patients had histopathologic, laboratory, and radiographic confirmation of stage II or III multiple myeloma by Salmon-Durie criteria. 13 Prior to enrollment, all patients had received at least one cytoreductive regimen and were treated to best clinical response. Patients were eligible if hepatic (serum bilirubin р2.0 mg/dl), pulmonary (FEV 1 у65% of predicted value for age), renal (serum creatinine р1.6 mg/dl), cardiac (left ventricular ejection fraction Ͼ45%), and performance status (0-2 SWOG scale) were within normal limits. Patients р60 years old were deemed eligible for an allogeneic transplant if a related, HLA-matched or one-antigen mismatched donor was available. Patients р70 years old were eligible for an autologous transplant. For patients eligible for either autologous or allogeneic transplant, the choice of graft was determined by patient preference. Protocols and consent forms were approved by the University of Michigan Institutional Review Board.
Mobilization and procurement of bone marrow and peripheral blood progenitor cells
Bone marrow was harvested under general anesthesia for the first six patients receiving allogeneic grafts. For the subsequent 15 patients, PBSC allografts were collected after mobilization with G-CSF (16 g/kg s.c. daily for 4 days). Donors were HLA-matched siblings in all cases except one (a one-antigen mismatch). For patients undergoing autologous transplantation, cyclophosphamide (4 gms/m 2 given i.v. over 2 h with MESNA for urothelial protection), was given with G-CSF (10 g/kg s.c. daily beginning on day 5) to aid in mobilization of PBSC. When the WBC was 1000/l and rising, PBSC were collected to a target dose of 5.0 × 10 6 CD34 + cells/kg. Five patients undergoing autologous PBSC harvest underwent CD34 + selection using the Baxter Isolex 300i system (Baxter Healthcare, Irvine, CA, USA) on a separate stem cell mobilization protocol.
Preparative regimen
All patients received modified TBI delivered by a linear accelerator using 15 MV photons in 1.5 Gy fractions twice daily on days −10, −9, −8 at a dose rate of 0.08 to 0.1 Gy/min (total dose 9 Gy). Patients were treated in the lateral decubitus position at a distance of 600 cm from the linear accelerator using anterior/posterior opposed beams. Customized blocks were used to shield the lung and liver tissue lateral to the vertebral bodies, and the shielded areas of the rib cage were treated using electrons. Patients who had received previous radiation were treated with full-dose TBI, as long as tolerance of the previously treated organs was respected. Busulfan 2.4 mg/kg was given p.o. in divided doses daily on days −7, −6, −5, and −4 (total dose 9.6 mg/kg). Cyclophosphamide 60 mg/kg was given once daily i.v. on days −3 and −2 (total dose 120 mg/kg). 12 
Graft-versus-host disease prophylaxis
Patients were eligible to enroll on separate GVHD prophylaxis and treatment protocols. Ten patients received tacrolimus alone for GVHD prophylaxis, six received tacrolimus and methotrexate, four received cyclosporine and methotrexate, and one received cyclosporine alone. Patients were given tacrolimus (0.03 mg/kg daily) or cyclosporine (3 mg/kg daily) by continuous intravenous infusion beginning day −1 and converted to oral dosing as tolerated. Blood levels of cyclosporine or tacrolimus were obtained twice weekly during the first 8 weeks of therapy and adjusted to maintain levels of 150-450 or 5-15 ng/ml, respectively. Dose reductions were based on toxicity as previously described.
14 After 8 weeks of therapy, the dose was tapered by 20% every 4 weeks and discontinued on day +181 if there were no signs of GVHD. For patients receiving methotrexate for GVHD prophylaxis, the decision to give the dose on days +1, +3, +6, and +11 was determined by severity of mucositis, presence of effusions, and degree of renal and liver dysfunction on the day of drug administration.
Supportive care
Patients receiving an allograft were treated with trimethoprim/sulfamethoxazole (double strength twice daily orally) and fluconazole (100 mg daily orally) for 7 days prior to admission for gastrointestinal decontamination. Both autologous and allogeneic patients were given prophylactic norfloxacin (400 mg twice daily orally) and fluconazole (100 mg once daily orally) beginning the day of admission. For patients who were HSV-antibody positive and CMV-antibody negative, acyclovir (400 mg three times daily orally or 5 mg/kg twice daily i.v.) was started on day of admission. Patients undergoing allogeneic transplant who were CMV antibody-positive received ganciclovir (5 mg/kg twice daily i.v.) at the time of admission and continued until day −1. With the first neutropenic fever, norfloxacin was discontinued and systemic antibiotics were initiated. G-CSF (5 g/kg once daily s.c.) was started on day +6 until neutrophil engraftment. For allogeneic transplant recipients, trimethoprim/sulfamethoxazole (double strength twice daily orally 3 days a week) was initiated upon discharge from hospital. If donor or patient was CMV-antibody positive, ganciclovir prophylaxis (5 mg/kg twice weekly i.v.) was restarted after neutrophil engraftment and continued until day +100.
Response criteria
Disease response was assessed prior to transplant, at day +100, and then annually or when clinically indicated using the following criteria. A complete response was defined as the absence of a monoclonal protein in serum or urine by immunofixation, Ͻ5% polyclonal plasma cells in the marrow aspirate, and the absence of new lytic bone lesions or plasmacytomas. A partial response was defined as at least a 50% decrease in the M-spike protein or percentage of plasma cells in the marrow aspirate with no new lytic bone lesions. Stable disease was a Ͻ50% decrease in the amount of monoclonal protein or percentage of plasma cells in the marrow aspirate with no new lytic bone lesions. Progressive disease was defined as an increase in the M-spike paraprotein or plasmacytosis of at least 50% above the 'plateau' level in two samples measured at least 4 weeks apart, the development of new lytic bone lesions or plasmacytomas, or the reappearance of a monoclonal plasmacytosis.
Statistical analysis
Progression-free and overall survivals were estimated according to the method of Kaplan-Meier, and compared by the log-rank test. 15, 16 Differences in categorical variables were determined by the 2 test or Fisher's exact test. Differences in continuous variables were determined by the Wilcoxon rank sum test. Cox regression was used to model the effect of covariates jointly on survival, with significance based upon a Wald test for each regression parameter.
Results

Patient characteristics
Patient characteristics are shown in Table 1 . Patients undergoing allogeneic transplant were younger than those undergoing autologous transplant, with median ages of 48 and 55 years, respectively (P Ͻ 0.01). Other characteristics including gender, number of regimens prior to transplant, median time from diagnosis to transplant, disease status at time of transplant, and immunoglobulin subtype were equally distributed between the groups.
Disease response, progression, and survival
The median duration of follow-up from allogeneic transplant was 832 days (range, 12-2054) compared to 467 days (range, 14-894) from autologous transplant (P = 0.01). Of the 21 patients in the allogeneic group, six (28%) were in CR prior to transplant and 14 (67%) after transplant. Of the 35 patients in the autologous group, nine (26%) were in CR prior to transplant and 13 (37%) after transplant. Compared to autologous transplantation, significantly more Bone Marrow Transplantation patients entered a CR or PR after allogeneic transplantation (P = 0.02) ( Table 2 ).
In the entire group of 56 patients, 15 developed progressive disease (one in the allogeneic group and 14 in the autologous group). The Kaplan-Meier probability of disease progression was 11% in the allogeneic group and 64% in the autologous group (P Ͻ 0.001) (Figure 1 ). In the allogeneic group, one patient progressed on day +971 with a plasmacytoma unresponsive to donor lymphocyte infusions (DLI) and required radiation therapy for disease control. In the autologous group, 14 patients developed progressive disease, and 11 subsequently died, while three patients are alive after receiving further therapy. Two of the five patients who received CD34 + selected PBSC developed evidence of progressive disease after transplant.
Progression-free (60% vs 30%, P = 0.19) and overall (60% vs 42%, P = 0.39) survival favored the allogeneic group, but did not reach a statistically significant level (Figures 2 and 3) . At the time of data analysis, median survivals had not been reached in either group. Age played a significant role in overall survival in the allogeneic group Table 2 Disease response according to treatment group Figure 1 The Kaplan-Meier probability of disease progression. P value according to log-rank test. only. For those р50 years of age at time of transplant, overall survival at 3 years was significantly higher than for patients Ͼ50 (79% vs 29%, P = 0.03) (Figure 4 ). There was no correlation between age and overall survival in the autologous group.
Autologous Allogeneic P value
Graft-versus-host disease (GVHD)
Ten patients developed acute GVHD (four grade II; six grades III-IV). The Kaplan-Meier estimate of acute GVHD was 55% for grade II-IV and 40% for grade III-IV. Sixteen patients developed chronic GVHD (five limited, 11 extensive). The probability of developing chronic GVHD was 65% at 1 year and 82% at 2 years. Among the patients with acute GVHD surviving past day 100, all but one developed chronic GVHD.
Causes of death
In the allogeneic group, eight patients (38%) have died. Four deaths occurred prior to day +100 (one each from aspiration pneumonia, sepsis, acute GVHD, and infectious pneumonitis), and four deaths occurred beyond day +100 (one each from chronic GVHD, necrotizing pneumonia, pneumococcal pneumonia, and metastatic colorectal cancer). None of these eight patients had evidence of progressive disease at the time of their death. In the autologous group, there were 13 deaths (37%). Two patients died from transplant-related toxicities (interstitial pneumonitis and multisystem organ failure) before day +100. Eleven patients died of disease progression. Although the Kaplan-Meier estimate of 100-day mortality was higher in the allogeneic group, it did not reach statistical significance (19% vs 9%, P = 0.41).
Multivariate analyses
In a multivariate analyses, a Cox regression model was used to examine the influence of the source of stem cell graft on overall and progression-free survivals, adjusting for age and the presence of progressive disease at the time of transplant. All three covariates were simultaneously considered in the model. The results of these analyses are summarized in Table 3 . Both age and disease at transplant were significant independent factors for OS and PFS. Patients older than 50 years or who had progressive disease at transplant did poorly. When source of the stem cell graft was examined adjusting for both age and progressive disease, there were no significant differences in either OS or PFS between the allogeneic and autologous patients. The allogeneic patients tended to have a better PFS while the autologous patients had a better OS, although the relative risks were not statistically significant.
Discussion
In this study, we compared two transplant trials for myeloma, one using allogeneic stem cells and the other autologous stem cells, to assess the impact of the stem cell source on outcome. Although the two patient groups were similar in gender, disease status at time of transplant, myeloma subtype, interval from diagnosis to transplant, and pretransplant therapy, the allogeneic patients were significantly younger. All patients were conditioned with a preparative regimen of busulfan, cyclophosphamide, and modified TBI.
The most significant finding of this study was the lower rate of disease progression seen in the allogeneic patient group compared to the autologous patient group. Only one of 21 patients undergoing allogeneic transplant developed progressive disease compared to 14 of 35 patients in the autologous group, a finding even more impressive given that the median follow-up was longer in the allogeneic group. This finding supports the presence of a clinically significant GVM effect and suggests that an allogeneic stem cell source may have a more significant impact on relapse rate than the preparative regimen. The low rate of disease progression in our allogeneic group is similar to rates reported in other studies using T cell-replete allografts. Bensinger et al 12 reported on 23 patients undergoing allogeneic transplant using the same preparative regimen of modified TBI, busulfan, and cyclo- phosphamide. Although the 100-day mortality was higher than our rate no patient died of progressive disease. Similarly, Kulkarni et al 17 reported on 33 patients undergoing allogeneic transplant of which 28 received a TBI-based preparative regimen. With a median follow-up of 27 months no surviving patient experienced disease progression. In spite of the low relapse rate in allogeneic transplants, the overall survival in studies which compare allogeneic to autologous transplant for myeloma often show no benefit because of the high incidence of non-relapse related complications associated with allogeneic transplantation.
In the autologous group, the Kaplan-Meier plot of overall survival (Figure 2 ) was shorter than the overall survivals reported in other studies. This may reflect differences in pretransplant risk factors, as well as the efficacy and the toxicity of our preparative regimen in heavily pretreated patients. The choice of our conditioning regimen was based on data which indicated that it had substantial antimyeloma activity in patients with chemo-refractory disease undergoing autologous transplant. 11 Although there has been no randomized trial showing a clearly superior preparative regimen for patients with myeloma undergoing autologous transplant, Desikan et al 18 suggested that a preparative regimen of melphalan (200 mg/m 2 ) was associated with a superior event-free and overall survival compared to regimens containing cyclophosphamide or TBI. In a heavily pretreated population undergoing autologous transplant, Barlogie et al 19 reported treatment-related mortality rates of 11% and 13% for patients receiving melphalan with or without TBI, respectively, which is equivalent to our rate of 9%. It is impossible to predict if a melphalan-based preparative regimen would have changed the OS and PFS in our trial.
The 100-day mortality rate of 19% for our allogeneic patients is consistent with mortality rates reported by others. Preliminary data from a review of the EBMT registry showed that allogeneic transplants for myeloma performed after 1994 had a transplant-related mortality rate of 21% compared to 38% prior to 1994. 20 The improvement in transplant-related mortality was partly attributed to improvements in supportive care. An additional factor which may have contributed to our low mortality rate and low rate of disease progression was the use of PBSC in 15 of 21 of our allogeneic patients. Recently, two randomized trials of bone marrow vs PBSC in allogeneic transplantation have suggested a lower relapse rate and survival advantage using PBSC. 21, 22 Our incidence of acute GVHD (55%) was similar to the rate reported in other studies using PBSC. 21, 22 At the time of analysis, only two of the eight deaths were attributable to GVHD. The rate of cGVHD (82% at 2 years), is somewhat higher than reported in other studies. Although this may have played a role in our low relapse rate, the number of patients in our study is small making it difficult to draw any conclusions.
While the benefit of autologous transplantation is based on a dose-response effect, the benefit of allogeneic transplantation includes a GVM effect. The most direct evidence of a GVM effect is provided by trials in which donor leukocyte infusions (DLI) induced remissions in patients relapsing after allogeneic transplant. [23] [24] [25] [26] In some cases, the dur-ations of these remissions have surpassed the durations of the initial responses to allogeneic transplant, and in one case a remission has exceeded 6 years. 23 In addition, multiple relapses after allogeneic transplant have been shown to respond repeatedly to DLI. 26 Finally, Martinelli et al 27 recently showed that patients are more likely to achieve a molecular CR after allogeneic transplant compared to autologous transplant, and that patients in a molecular CR have a significantly longer relapse-free survival compared to patients not in molecular CR (110 vs 35 months, P Ͻ 0.005). Even though the data are limited, these observations can be taken as proof of principle of a GVM effect. For patients with multiple myeloma and an HLA-compatible donor, choosing between an allogeneic transplant and an autologous transplant may be difficult. Our data show that given an identical preparative regimen of TBI, busulfan, and cyclophosphamide, an allogeneic transplant significantly reduces disease progression compared to autologous transplant. However this was not a randomized trial and caution must be used in comparing the groups. The allogeneic patients were significantly younger than the autologous patients. In addition, other differences may exist which contributed to the different rates of disease progression. When we examined overall and progression-free survival by a Cox regression model and adjusted for age, type of graft, and disease status, no benefit was found with an allogeneic transplant. Although there was a suggestion that progression-free survival was improved with an allogeneic transplant, it did not achieve statistical significance. Results from our subset analyses of the allogeneic group revealed superior 5-year overall survival for patients of 50 years and under compared to patients over 50 years. The poor outcome in the older patients was due to procedurerelated complications as opposed to disease progression, demonstrating the morbidity of full-intensity allogeneic transplantation in older patients. Newer, less-intense preparative regimens should reduce the toxicity of allogeneic transplantation which may, in turn, improve the outcome compared to autologous transplantation.
